EUVIMEDEUVIMED entdecken
Crossref

Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles

Takato Masada, Kohdai Yamada, Saito Akei, Keiko Minami, Toshihide Takagi, Shinji Yamashita, Makoto Kataoka

Journal of Pharmaceutical Sciences · 2026

DOI: 10.1016/j.xphs.2026.104191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmaceutical Sciences, 2026. Verfasst von Takato Masada und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan. Hauptthemen laut MEDLINE: Cilostazol, Parabens, Gastric Absorption, Gastric Mucosa. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The present study investigated dose-dependent effects on the oral absorption of cilostazol (CIL) from cocrystals with 4-hydroxybenzoic acid (4HBA) and attempted to mitigate these effects by adding an excess amount of intact 4HBA. With increasing CIL-4HBA doses in rats, the relative maximum plasma concentration (Cmax) decreased and the time to Cmax (Tmax) was prolonged. Although the supersaturation and precipitation of CIL were noted in fasted-state simulated gastric fluid, their extent was not dependent on its dose. However, the dissolved fraction of 4HBA, an indicator of cocrystal dissolution, significantly decreased with increasing doses. An analysis of solubility products indicated that at high doses, both components rapidly reached the equilibrium solubility of CIL-4HBA, markedly reducing the dissolution rate. These in vitro results support the reduced absorption rate of CIL. To mitigate dose-dependent effects, a physical mixture of CIL-4HBA with excess 4HBA was evaluated. Cocrystal dissolution in the stomach was strongly suppressed, which led to the disappearance of differences in relative Cmax and Tmax. These results suggest that solubility products in the stomach govern CIL absorption from cocrystals and also that the addition of an excess amount of an intact coformer effectively mitigates dose-dependent absorption behavior.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CilostazolParabensGastric AbsorptionGastric MucosaAnimalsSolubilityCrystallizationMaleRatsDose-Response Relationship, DrugAdministration, OralRats, Sprague-DawleyIntestinal Absorption

Stichwörter der Autor:innen

Co-crystalDissolutionPoorly water-soluble drugPrecipitationSupersaturation

Substanzen

CilostazolParabens4-hydroxybenzoic acid

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan.
  • Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan. Electronic address: makoto@pharm.setsunan.ac.jp.

Zitieren

APA

Masada, T., Yamada, K., Akei, S., Minami, K., Takagi, T., Yamashita, S., & Kataoka, M. (2026). Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2026.104191

Vancouver

Masada T, Yamada K, Akei S, Minami K, Takagi T, Yamashita S, et al. Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles. Journal of Pharmaceutical Sciences. 2026. doi:10.1016/j.xphs.2026.104191

BibTeX
@article{Masada2026,
  author = {Masada, Takato and Yamada, Kohdai and Akei, Saito and Minami, Keiko and Takagi, Toshihide and Yamashita, Shinji and Kataoka, Makoto},
  title = {Mitigation of dose-dependent cilostazol absorption from cocrystals: A coformer regulates gastric dissolution and absorption profiles},
  journal = {Journal of Pharmaceutical Sciences},
  year = {2026},
  doi = {10.1016/j.xphs.2026.104191}
}
Kostenlos starten →